Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial

Author:

Tavenier Anne H,Hermanides Renicus S1,Ottervanger Jan Paul1,Tolsma Rudolf2ORCID,van Beurden Antony3,Slingerland Robbert Jan4,ter Horst Peter G J5,Gosselink A T Marcel1,Dambrink Jan-Henk E1,van Leeuwen Maarten A H1,Roolvink Vincent1ORCID,Kedhi Elvin6,Klungel Olaf H7,Belitser Svetlana V7,Angiolillo Dominick J8,Pustjens Tobias910ORCID,Rasoul Saman910ORCID,Gho Ben10,Stein Mera10,Ruiters Lex10,van ‘t Hof Arnoud W J1910

Affiliation:

1. Department of Cardiology, Isala Hospital, dr. van Heesweg 2, 8025 AB Zwolle, The Netherlands

2. Ambulancedienst IJsselland, Voltastraat 3-A, 8013 PM Zwolle, The Netherlands

3. GGD Zuid-Limburg, Heerlen, The Netherlands

4. Department of Clinical Chemistry, Isala, Zwolle, The Netherlands

5. Department of Clinical Pharmacy, Isala, Zwolle, The Netherlands

6. Department of Cardiology, AZ Sint-Jan, Brugge, Belgium

7. Department of Pharmacoepidemiology, University of Utrecht, Utrecht, The Netherlands

8. Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA

9. Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands

10. Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands

Abstract

Abstract Aims Platelet inhibition induced by P2Y12 receptor antagonists in patients with ST-elevation myocardial infarction (STEMI) can be affected by concomitant use of opioids. The aim of this trial was to examine the effect of intravenous (iv) acetaminophen compared with iv fentanyl on P2Y12 receptor inhibition in patients with STEMI. Methods and results The Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial randomized 195 STEMI patients who were scheduled to undergo primary percutaneous coronary intervention (PCI) and were pre-treated with crushed ticagrelor to iv acetaminophen (N = 98) or iv fentanyl (N = 97) in the ambulance. The primary endpoint, consisting of the level of platelet reactivity units (PRU) measured immediately after primary PCI, was not significantly different between the study arms [median PRU 104 (IQR 37–215) vs. 175 (63–228), P = 0.18]. However, systemic levels of ticagrelor were significantly higher in the acetaminophen arm at the start of primary PCI [151 ng/mL (32–509) vs. 60 ng/mL (13–206), P = 0.007], immediately after primary PCI [326 ng/mL (94–791) vs. 115 ng/mL (38–326), P = 0.002], and at 1 h after primary PCI [488 ng/mL (281–974) vs. 372 ng/mL (95–635), P = 0.002]. Acetaminophen resulted in the same extent of pain relief when compared with fentanyl [reduction of 3 points on 10-step-pain scale before primary PCI (IQR 1–5)] in both study arms (P = 0.67) and immediately after PCI [reduction of 5 points (3–7); P = 0.96]. Conclusion The iv acetaminophen in comparison with iv fentanyl was not associated with significantly lower platelet reactivity in STEMI patients but resulted in significantly higher ticagrelor plasma levels and was effective in pain relief.

Funder

AstraZeneca and the Isala Academy

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Antithrombotic therapy for patients with STEMI undergoing primary PCI;Franchi;Nat Rev Cardiol,2017

2. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial;Kubica;Eur Heart J,2016

3. The on- and off-target effects of morphine in acute coronary syndrome: a narrative review;McCarthy;Am Heart J,2016

4. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention;Parodi;Circ Cardiovasc Interv,2014

5. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention;Sibbing;JACC Cardiovasc Interv,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3